HMGA2
Overview
HMGA2 (High Mobility Group AT-Hook 2) is a chromatin-associated non-histone protein that regulates gene expression by altering chromatin architecture. It is recurrently altered in multiple cancers and was identified as a candidate RTK-pathway or amplification target in head and neck squamous cell carcinoma.
Alterations observed in the corpus
- Listed among candidate alterations in HNSCC (Fig. 3) PMID:25631445
- 3 recurrent fusions identified in cutaneous melanoma (PCBP2-HMGA2, TSFM-HMGA2, SENP1-HMGA2) in the TCGA 333-sample multi-platform characterisation study PMID:26091043
- Chromosomal rearrangements in 4/23 endometrial polyps (intragenic in 2); average VAF 0.24; partners include LRMDA, RAD51B, and TRAF3IP2; protein overexpression by IHC in 3/3 HMGA2-only-rearranged polyps; mRNA upregulation did not reach significance (p=0.37) PMID:28445112
- 12q13~15 amplification in 76% of dedifferentiated liposarcoma (DDLPS, n=50), co-amplified with MDM2, CDK4, FRS2, and NAV3 in TCGA SARC. PMID:29100075
Cancer types (linked)
- Per cancer type: prevalence, co-mutation patterns, clinical significance.
Co-occurrence and mutual exclusivity
- Linked partner genes with the relationship and the paper(s) reporting it.
Therapeutic relevance
- Drugs (linked) targeting this gene or its pathway, with the studies supporting them.
Open questions
- Conflicts or unresolved findings across papers.
Sources
This page was processed by entity-page-writer on 2026-05-14. - PMID:26091043
This page was processed by wiki-cli on 2026-05-14. - PMID:28445112
This page was processed by wiki-cli on 2026-05-14. - PMID:29100075
This page was processed by entity-page-writer on 2026-05-15.